<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379742</url>
  </required_header>
  <id_info>
    <org_study_id>Thin-1</org_study_id>
    <nct_id>NCT01379742</nct_id>
  </id_info>
  <brief_title>Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy</brief_title>
  <official_title>Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostate Cancer Foundation of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prostate Cancer Foundation of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate health related quality of life factors in patients undergoing low&#xD;
      dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for&#xD;
      use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel,&#xD;
      sexual function and bother will be measured by the EPIC questionnaire at various time&#xD;
      intervals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health related quality of life including urinary, bowel and sexual function as measured by the EPIC questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Randomized</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Iodine-125 standard 18 g needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapidstrand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 g needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thin Strand</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RapidStrand seeds for use with 18g needle</intervention_name>
    <description>Rapidstrand seeds are standard size and are used with 20 g needles</description>
    <arm_group_label>20 g needle</arm_group_label>
    <arm_group_label>Iodine-125 standard 18 g needle</arm_group_label>
    <other_name>Both Rapidstrand and Thinstrand are manufactured by Oncura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ThinStrand</intervention_name>
    <description>ThinStrand seeds are smaller in diameter and used with 20g needles</description>
    <arm_group_label>20 g needle</arm_group_label>
    <arm_group_label>Iodine-125 standard 18 g needle</arm_group_label>
    <other_name>Both ThinStrand and RapidStrand are manufactured by Oncura.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b, N0,&#xD;
             M0&#xD;
&#xD;
          -  Greater than or equal to 40 years of age&#xD;
&#xD;
          -  Low and Low- Intermediate Risk prostate cancer&#xD;
&#xD;
          -  Prostate volumes by TRUS ≤ 60 cc&#xD;
&#xD;
          -  I-PSS score &lt; 25 (alpha blockers allowed)&#xD;
&#xD;
          -  Signed study-specific informed consent form prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymph node involvement (N1)&#xD;
&#xD;
          -  Evidence of distant metastases (M1)&#xD;
&#xD;
          -  Radical surgery for carcinoma of the prostate&#xD;
&#xD;
          -  Prior pelvic radiation&#xD;
&#xD;
          -  Major medical or psychiatric illness, which in the investigator's opinion would&#xD;
             prevent completion of treatment and would interfere with follow- up or ability to&#xD;
             complete questionnaires&#xD;
&#xD;
          -  Hip prosthesis&#xD;
&#xD;
          -  Inability or refusal to provide informed consent&#xD;
&#xD;
          -  Evidence of Previous TURP&#xD;
&#xD;
          -  Prior hormone therapy&#xD;
&#xD;
          -  Prior TURP&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J Moran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chicago Prostate Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chicago Prostate Center</name>
      <address>
        <city>Westmont</city>
        <state>Illinois</state>
        <zip>60559</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian J Moran, MD</last_name>
      <phone>630-654-2515</phone>
      <email>seeds@prostateimplant.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle H Braccioforte, MPH</last_name>
      <phone>630-366-7860</phone>
      <email>mbraccioforte@prostateimplant.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>prostate brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

